Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentBusiness Wire • 04/16/24
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyBusiness Wire • 03/19/24
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugBusiness Wire • 02/06/24
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®Business Wire • 01/31/24
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/22/23
UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck CancerBusiness Wire • 12/04/23
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory ApprovalsBusiness Wire • 10/24/23
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023Business Wire • 10/23/23
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale ProductionBusiness Wire • 10/19/23
CEL-SCI Files Request With the UK's MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck CancerBusiness Wire • 10/05/23
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck CancerBusiness Wire • 09/26/23
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck CancerBusiness Wire • 07/14/23